Navigation Links
Anesiva Names Michael L. Kranda as President, Chief Executive Officer and Member of Its Board of Directors
Date:6/16/2008

management," said Mr. Kranda. "I look forward to working with the talented employees of Anesiva to achieve these goals and build long-term value for stockholders."

"The members of the Anesiva board welcome Michael and thank John for his dedicated leadership over the last 8 years," said Mr. Ferguson. "We appreciate John's vision and dedication in leading Anesiva."

"I am proud of the significant accomplishments that the Anesiva team has made over the last several years," said Mr. McLaughlin. "With Michael in place to lead the company forward, I will work closely with him as a consultant to ensure a smooth transition."

About Anesiva's Diverse Pipeline of Pain Products

Anesiva, Inc. is a commercial-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company's first product, Zingo(TM), is scheduled for launch later this month in the U.S. for the reduction of pain associated with peripheral venous access procedures in children ages three to 18. The company filed an sNDA with the FDA to expand the label to include adults in March 2008.

The next product in Anesiva's pipeline, Adlea(TM), is currently being evaluated in two pivotal Phase 3 clinical trials to support an indication for the management of acute pain following orthopedic surgery. Adlea has been shown to reduce pain after only a single administration for weeks to months in multiple settings in mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain.

Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.

Forward Looking Statements

This press release includes "forward-look
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
5. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
6. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
7. Anesiva Raises $45 Million in Common Stock Offering
8. Anesiva Announces Completion of Common Stock Offering
9. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
10. Anesiva Appoints Daniel Janney to Board of Directors
11. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013 The congress ... Transplant Association) is the biggest congress in ... Nearly 10,000 participants are in Istanbul ... research findings. New pioneering studies have been presented: ... PYROPHOSPHATE (SFP) ADMINISTERED VIA HEMODIALYSATE REDUCES ESA USE" ...
(Date:5/21/2013)... Savoury Systems International (SSI), a leader ... to Southeastern USA Sales Broker. Braddy’s new role will ... the Southeast. , In 2004 Braddy founded ... to food processors and industrial manufacturers. Braddy has ... industry and has over 25 years of sales management ...
(Date:5/21/2013)... 21, 2013 Clinverse, Inc. ... for clinical trials, announced today it has formed ... Clinverse’s ClinPay® FLS eClinical commerce platform aggregates ... SpendMD ™, Aggregate Spend Solutions’ recently-launched ... tracking and reporting transfer of value at investigator ...
(Date:5/21/2013)... 2013 Smarter Security, Inc., provider of ... announced that Genzyme, a Sanofi company and leading biotech ... CL for a multi-use facility in the United States. ... Genzyme buildings, this latest order underscores the satisfaction and ... detection device improving doorway access control. , ...
Breaking Biology Technology:ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 3Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3
... for Continued Long-Term Growth, Conference Call and Webcast to Be Held Today at 5:00 p.m. ET (22:00 CET), ... Q3 2008 ... 190.5% increase Naglazyme Net Product ... 56.3% increase Aldurazyme Net Sales by Genzyme ...
... NVAX ) a clinical-stage vaccine company, announced today that ... presenting at,the BIO Investor Forum 2008 at 8:30 am. ... San Francisco, California. Dr. Singhvi will provide an,overview of ... the live presentation can be accessed via the Company ...
... quarter (26%) of primary care patients 40 years of age ... had airflow ... - Percentages were greater with increasing patient age and smoking ... findings from a cross-sectional study which showed,that 26 percent of ...
Cached Biology Technology:BioMarin Announces Third Quarter 2008 Financial Results 2BioMarin Announces Third Quarter 2008 Financial Results 3BioMarin Announces Third Quarter 2008 Financial Results 4BioMarin Announces Third Quarter 2008 Financial Results 5BioMarin Announces Third Quarter 2008 Financial Results 6BioMarin Announces Third Quarter 2008 Financial Results 7BioMarin Announces Third Quarter 2008 Financial Results 8BioMarin Announces Third Quarter 2008 Financial Results 9BioMarin Announces Third Quarter 2008 Financial Results 10BioMarin Announces Third Quarter 2008 Financial Results 11BioMarin Announces Third Quarter 2008 Financial Results 12New Research Shows Many Patients with Persistent Cough and Sputum Actually had Airway Obstruction Consistent with COPD 2New Research Shows Many Patients with Persistent Cough and Sputum Actually had Airway Obstruction Consistent with COPD 3New Research Shows Many Patients with Persistent Cough and Sputum Actually had Airway Obstruction Consistent with COPD 4
(Date:5/21/2013)... path of insulin action in cells in precise detail ... understanding what goes wrong in diabetes. , The ... James from Sydney,s Garvan Institute of Medical Research, is ... prestigious journal Cell Metabolism . , First discovered ... role in the body because it helps us lower ...
(Date:5/21/2013)... ANDOVER, Mass. , May 21, 2013 ... that CX50 xMATRIX, the world,s first portable ultrasound with ... Intracardiac Echo (ICE) capability. The CX50 xMATRIX with available ... Paris at the EuroPCR, official ... (EAPCI), May 21-24. Since its launch in ...
(Date:5/21/2013)... the way genes function without changing the underlying ... blood of pregnant women during any trimester, potentially ... the weeks after giving birth, and an opportunity ... findings of the small study involving 52 pregnant ... Molecular Psychiatry . , "Postpartum depression can be ...
Breaking Biology News(10 mins):Insight into the dazzling impact of insulin in cells 2Insight into the dazzling impact of insulin in cells 3Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3
... from the University of Leeds has identified how the virus which ... a possible new treatment for the disease. , Kaposi,s Sarcoma ... widespread in sub-Saharan Africa, where it is the most common cause ... Faculty of Biological Sciences found that a human protein known ...
... them locate the big catch. Now Tel Aviv University researchers ... help scientists accelerate their research into new fat-melting drugs. ... of the journal Tissue Engineering , fits onto a ... to measure a broad number of physical parameters in the ...
... (AML) is relatively rare in children, drinking alcohol during ... paper published in Cancer Epidemiology, Biomarkers & Prevention ... Research. Julie Ross, Ph.D., director of the division ... of Minnesota, said there are about 700 cases of ...
Cached Biology News:A 'fat forward' research tool 2
... InnoScan700 is a fluorescence scanner with ... biochip (Staggered/Orange Packing, Protein, CGH, ) spotted ... the range of InnoScan700 scanners include three ... InnoScan700A is a simultaneous dual fluorescence scanner ...
... DNAscope is an integrated confocal laser scanner ... integrated into your specific application. GeneFocus can ... tailor the system to your specifications. ... design has been modularized and built onto ...
... Hybridization chambers with forced convection Temperature range ... to 99.9 C / 212 F Patented ... results DS controller Timer 0 to ... accuracy of a tenth of a degree ...
... tubes provide a fast, easy to use, ... counting. They are 15 times faster and ... less than 5%). ,The VoluPAC tubes enable ... (PCV) in a cell suspension, resulting in ...
Biology Products: